Nanoparticle delivery of a pH-sensitive prodrug of doxorubicin and a mitochondrial targeting VES-H₈R₈ synergistically kill multi-drug resistant breast cancer cells

Petro Czupiel¹²³, Vianney Delplace¹²³ & Molly Shoichet¹²³✉

Multi-drug resistance (MDR) remains a major obstacle in cancer treatment while being heavily dependent on mitochondrial activity and drug efflux. We previously demonstrated that cationic lipids, such as the vitamin E succinate modified octahistidine-octaarginine (VES-H₈R₈) conjugate, target mitochondria, resulting in depolarized mitochondria and inhibited drug efflux in MDR breast cancer cells. We hypothesized that the effective cell uptake, efflux inhibition, and mitochondrial depolarization properties of VES-H₈R₈ would synergistically enhance the toxicity of a pH-sensitive prodrug of doxorubicin (pDox) when co-encapsulated in nanoparticles (NPs). pDox was successfully synthesized and validated for pH-sensitive release from NPs under lysosome-mimicking, acidic conditions. The synergistic effect of VES-H₈R₈ and pDox was confirmed against MDR breast cancer cells in vitro. Importantly, synergism was only observed when VES-H₈R₈ and pDox were co-encapsulated in a single nanoparticulate system. The synergistic mechanism was investigated, confirming superior pDox uptake and retention, Pgp efflux inhibition, mitochondrial depolarization, and enhanced induction of ROS, and apoptosis. This work demonstrates the translational potential of doubly-loaded NPs co-encapsulating pDox with VES-H₈R₈ to synergistically kill MDR breast cancer cells.

Multi-drug resistance (MDR) remains a major obstacle in cancer treatment whereby MDR cancer cells are able to survive and proliferate under clinical doses of chemotherapeutic agents¹. MDR can be intrinsic or acquired, and results in cross-resistance to multiple chemotherapeutics. Intrinsic MDR arises from hyperactive detoxification processes that counteract the mechanisms of action of chemotherapies such as oxidant scavenging or regulation of pro-apoptotic proteins²³. Nonspecific acquired resistance arises when cancer cells overexpress drug efflux pumps, such as breast cancer resistance protein, multidrug resistance-associated protein, and permeation glycoprotein (Pgp)⁴⁻⁶. For example, Pgp expression in cancer tissue is increased from 11% in untreated patients to 30% in patients who underwent chemotherapy, resulting in an increased prevalence of MDR tumors⁷. Drug efflux is an active process, requiring adenosine triphosphate (ATP) for pumping various chemotherapeutics out of the cell, lowering the effective intracellular drug concentration⁸. Both intrinsic and acquired MDR are heavily dependent on the mitochondria, making the mitochondria of MDR cancer cells an attractive intracellular target. Interestingly, the mitochondria of cancer cells are hyperpolarized, opening new opportunities for tumor targeting⁹. For example, Neu4145 cancer cells exhibit a mitochondria membrane potential of −210 mV, whereas the mitochondrial membrane potential of non-cancer cells ranges around −138 mV¹⁰⁻¹¹. Furthermore, MDR cancer cells are able to retain active and polarized mitochondria following chemotherapy treatment, allowing electrophoretic targeting of MDR cancer cells¹². Traditionally, delocalized lipophilic cations (DLCs), such as triphenylphosphine- and guanidine-containing compounds (e.g., arginine), are used to electrophoretically target mitochondria. Mitochondrial-penetrating peptides, composed of alternated hydrophobic and...
cationic amino acids, have also been designed to deliver chemotherapeutics specifically to mitochondria, showing enhanced chemotherapeutic activity\textsuperscript{13}. Most recently, we developed a vitamin E succinate modified octahistidine-octaarginine (VES-H\textsubscript{8}R\textsubscript{8}) conjugate with similar structural features that targets cancer mitochondria and exhibits selective toxicity in MDR cancer cells\textsuperscript{14}. VES-H\textsubscript{8}R\textsubscript{8} was demonstrated to kill MDR cancer cells via mitochondria depolarization, induction of reactive oxygen species (ROS), apoptosis, and G1 cell cycle arrest. Importantly, VES-H\textsubscript{8}R\textsubscript{8} demonstrated good cell uptake, retention and Pgp efflux inhibition in MDR cancer cells, which makes VES-H\textsubscript{8}R\textsubscript{8} an ideal candidate for co-delivery with other chemotherapeutics, such as doxorubicin, for potential synergism.

Nanoparticles (NPs) carry many advantages, such as solubilization of hydrophobic therapeutics, passive tumor targeting via the enhanced permeability and retention effect, and, importantly, encapsulation of multiple therapeutics\textsuperscript{15-17}. Moreover, relative to free drug combinations, drug co-encapsulation strategies offer novel and enhanced therapeutic advantages in the clinical setting\textsuperscript{18}. Free drug combinations do not guarantee optimal drug ratios in diseased tissues as drugs typically have differing metabolism, pharmacokinetics, and tumor uptake. On the contrary, co-encapsulating drugs in NPs allows spatiotemporal control in vivo, wherein the initial drug ratio is maintained from the injection site to the tumor. For example, the co-encapsulation of doxorubicin and mitomycin C in NPs was therapeutically superior to free drug combination in vivo, with prolonged systemic circulation, enhanced tumor accumulation, and maintenance of synergistic drug ratios over 24 h\textsuperscript{19}. The synergistic co-encapsulation of cytarabine and daunorubicin also demonstrated clinical success against high-risk acute myeloid leukemia (AML), and is the first nanotherapy in 40 years to improve the survival of patients with AML\textsuperscript{20,21}. Thus, NPs are suitable carriers for multiple drugs and support synergistic anti-cancer activity against tumors.

We explored, for the first time, the potential synergism of co-encapsulated VES-H\textsubscript{8}R\textsubscript{8} and doxorubicin in an MDR breast cancer model. As doxorubicin hydrochloride is water soluble (>50 mg/mL) and rapidly leaks out of NPs, we envisioned to use a pH-sensitive, hydrophobic prodrug of doxorubicin that is suitable for encapsulation\textsuperscript{22,23}. Using a hydrazone linkage, the palmityl-modified doxorubicin (pDox) is expected to be water-insoluble at neutral pH while releasing doxorubicin from NPs in the acidic endolysosomal environment upon cancer cell uptake\textsuperscript{24,25}. We hypothesized that co-encapsulating VES-H\textsubscript{8}R\textsubscript{8} with pDox in NPs would lead to synergism in MDR cancer cells (Fig. 1). To test this hypothesis, pDox was synthesized and tested for pH release in lysosome-mimicking, acidic medium when encapsulated in NPs. The synergistic co-encapsulation of VES-H\textsubscript{8}R\textsubscript{8} and pDox was tested against both parental and MDR breast cancer cells\textsuperscript{18}. The synergistic mechanism of VES-H\textsubscript{8}R\textsubscript{8} and pDox was investigated through NP uptake and retention, Pgp efflux inhibition, mitochondria depolarization, induction of ROS, and cell death mechanism. This work demonstrates the synergistic mechanism of co-encapsulating a novel mitochondrial depolarizer and Pgp efflux inhibitor, VES-H\textsubscript{8}R\textsubscript{8}, with a pH-sensitive prodrug of doxorubicin in NPs against MDR cancer cells.

**Materials and Methods**

All solvents and reagents were purchased from Sigma-Aldrich and used as received unless otherwise noted. Peptide synthesis reagents were purchased from AnaSpec (Fremont, CA).

**Vitamin E Succinate modified Octahistidine-Octaarginine (VES-H\textsubscript{8}R\textsubscript{8}) synthesis.** VES-H\textsubscript{8}R\textsubscript{8} was synthesized as previously reported\textsuperscript{15}. Briefly, H\textsubscript{8}R\textsubscript{8} was synthesized by conventional solid-phase microwave assisted peptide synthesis techniques (CEM Liberty 1) on a rink amide ProTide Resins were used (CEM Corp, NC, USA). The N-terminus of H\textsubscript{8}R\textsubscript{8} was modified using 5.0 eq. of vitamin E succinate activated with 4.9 eq of 2-(6-Chloro-1-H-benzotriazole-1-yl)-1,1,3,3-tetramethyl ammonium hexafluorophosphate (HCTU) for 24 h. After washing the resin, the peptide was cleaved using TFA:H2O:TIS (95:2.5:2.5) for 5 hours and purified through a C18 reverse phase column (Silicycle, Quebec, Canada). Peptide mass was verified through Electrospray ionization or matrix assisted laser desorption ionization-time of flight mass spectrometry using the Agilent 6538 Q-TOF mass spectrometer.

**Palmitoyl-Doxorubicin synthesis.** Palmitic acid hydrazide was reacted with the ketone of doxorubicin, to produce the pH-sensitive hydrazone bond containing palmitoyl-doxorubicin (pDox), as synthesized previously (Fig. S1A)\textsuperscript{22,24}. Briefly, 150 mg of doxorubicin free base (MedKoo Biosciences, Inc, NC, USA) and 82 mg of Palmitic acid hydrazide (1.1 eq) were added to 300 mL of MeOH:DCC solution (1:1) containing 15 mL of trifluoroacetic acid. The reaction proceeded for 24 hours and reaction progress monitored by thin layer chromatography (TLC) using MeOH:DCC (1:3). After the reaction was complete, the solvent was removed by rotary evaporation, and the crude was dissolved in a small volume of MeOH:DCC (1:20). The dissolved crude was purified by silica column chromatography using DCM, and eluting with increasing concentrations of MeOH until the product, pDox, was eluted. Fractions containing pDox were collected, solvent removed by rotary evaporation, and placed in a vacuum dry oven to yield a red oil (yield 65%). The H NMR spectrum of pDox exhibited chemical shifts of δ 10.01 (1H, s), 8.03 (1H, s), 7.78 (1H, s), 5.5–5.52 (2H, d), 4.68 (2H, d), 3.91–4.09 (3H, m), 3.08–3.46 (6H, m), 2.03–2.60 (7H, m), 1.67–1.98 (8H, m), 1.02–1.42 (29H, m), 0.85–0.88 (6H, m) ppm. (Fig. S1B) The molecular ion peak ([M + H]+) of pDox was 796.63. (Fig. SIC)

**Polymer synthesis.** Poly(DL-lactide-co-2-methyl-2-carboxytrimethylene carbonate)\textsubscript{12K}-graft poly(ethylene glycol)\textsubscript{108}-azide (P(LA-co-TMCC)-g-PEG\textsubscript{N3}) was synthesized following previously established protocols\textsuperscript{6,12}. Briefly, a ring opening polymerization of DL-lactide and 2-methyl-2-carboxy-trimethylene carbonate catalyzed by a thiourea and initiated by a pyrenebutanol affords P(LA-co-TMCC) with a molecular weight of ~12,000 g/mol. 10,000 g/mol PEG chains are grafted onto the backbone by carbodimide chemistry. There were ~2 PEGs/ backbone as determined by H NMR.
Nanoparticle preparation. 20 wt% of VES-H₈R₈ and 25 wt% of pDox were added to 6 mg of P(LA-co-TMCC)-g-PEG-N₃ in 100 µL of methanol:acetonitrile solution (1:1), and then diluted with 2 mL of dH₂O. Singly loaded NPs were prepared using an identical NP protocol as before, except only one drug was added at the same wt%. Prepared NPs were filtered through a 0.45 µm PES filter, and aliquots were frozen until required. The diameters and zeta potential of NPs were measured using a Malvern Zetasizer Nano ZS (4 mW, 633 nm laser) at a concentration of 1 mg/mL.

Drug loading characterization. NP formulations containing pDox were quantified by fluorescence using the Tecan Infinite M200 Pro fluorescent plate-reader. NP formulations were diluted in DMSO:PBS (200:25), and pDox encapsulation was quantified by fluorescence measurement (ex/em 480/580 nm) against a standard curve. VES-H₈R₈ encapsulation was quantified using amino acid analysis. Average drug loading was obtained from three separate NP batches, calculated as follows:

**Figure 1.** Schematic representation of the proposed mechanism of synergy of co-encapsulated vitamin E succinate modified octahistidine-octaarginine (VES-H₈R₈) and palmityl-doxorubicin (pDOX). (i) Structure of poly(D,L-lactide-co-2-methyl-2-carboxytrimethylene carbonate)₁₂K-g-poly(ethylene glycol)₁₀K (P(LA-co-TMCC)-g-PEG) used as amphiphilic polymer for NP synthesis. (ii) Structure of vitamin E succinate modified octahistidine-octaarginine (VES-H₈R₈), with vitamin E succinate in red and octahistidine-octaarginine in blue. (iii) Structure of the pH-responsive, palmityl-doxorubicin (pDOX), with doxorubicin in pink, palmityl moiety in green, and the pH-responsive hydrazone bond in black. VES-H₈R₈ and pDOX loaded NPs (VDNPs) enter cells through the endolysosomal pathway where VES-H₈R₈ and hydrolyzed pDOX escape into the cytosol. VES-H₈R₈ affects the mitochondria and decreases the mitochondrial membrane potential. VES-H₈R₈ inhibits the permeation glycoprotein (Pgp) efflux of Dox, allowing the cytosolic accumulation of Dox. Accumulated Dox poisons topoisomerase II and, together with VES-H₈R₈, synergistically kills multi-drug resistant breast cancer cells.
Drug Loading(%) = \frac{\text{Mass}_{\text{pDox}} + \text{Mass}_{\text{VHR}}}{\text{Mass}_{\text{pDox}} + \text{Mass}_{\text{VHR}} + \text{Mass}_{\text{polymer}}} \times 100

pDox release study. Doxorubicin control, singly loaded NPs, DNPs, or doubly loaded NPs, VDNPs, were diluted in either PBS (pH = 7.4) or PBS/citric acid (pH = 5.0) at a polymer concentration of 100 μg/mL and sealed in dialysis tubing (Spectra/Por 6, 3.5 kDa, Spectrum Labs, CA, USA). The formulations were then allowed to dialyze against 40 mL of either PBS (pH = 7.4) or PBS/citric acid (pH = 5.0), under shaking at 37 °C. At indicated times, 25 μL of the dialysate was taken, diluted with 200 μL of DMSO before fluorescence measurement (ex/em: 480/580 nm) as a proxy for Dox release. After 48 h, the remaining encapsulated pDox was quantified as above. Three batches of each formulation were tested. Released Dox was calculated as follows:

\text{Released Dox(%) =} \frac{\text{Fluorescence Intensity of Dox}_{\text{Dialysate at Time X}}}{\text{Fluorescence Intensity of pDox}_{\text{Encapsulated at 48 h}}} \times 100

Cell cultures. Both WT (EMT6/P) and doxorubicin resistant (EMT6/AR1) EMT6 cells were generously provided by Dr. X.Y. Wu at the University of Toronto, originally from Dr. Ian F. Tannock at the Ontario Cancer Institute, (Toronto, ON, Canada) and maintained in our laboratory. Non-cancerous fibroblast cells (NIH/3T3) were grown in DMEM supplemented with 10% fetal calf serum and 1% penicillin/streptomycin at 37 °C in a humidified incubator with 5% CO2 atmosphere. EMT6/P cells were grown in α-MEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37 °C in a humidified incubator with 5% CO2 atmosphere. EMT6/AR-1 cells were grown as EMT6/P, with the addition of doxorubicin at 1 μg/mL to maintain doxorubicin resistance and Pgp overexpression.

NP potency assay. Cells were seeded into 96-well flat-bottomed tissue culture plates at a density of 3,000 cells per well, and allowed to adhere for 24 hours. Treatments were incubated with cells for 24 hours, then replenished with fresh media and incubated for an additional 48 hours. Singly-loaded NPs, DNPs and VDNPs, were dose-matched to the respective drug concentration of doubly loaded NPs, VDNPs. Free doxorubicin was used as a control where doxorubicin hydrochloride was dissolved in dimethylsulfoxide (DMSO) at a concentration of 1 mg/mL. Free VES-H8R8 was also used as a control dissolved in DMSO at a concentration of 1 mg/mL. After the addition of NP formulations, cells were allowed to grow for 24 h at 37 °C in a 5% CO2, and 95% air humidified incubator. The Presto Blue (Life Technology) assay was used as a proxy for cell relative viability, calculated as follows:

\text{Relative Viability(%) =} \frac{\text{Fluorescence Intensity}_{\text{Treated}}}{\text{Fluorescence Intensity}_{\text{Untreated}}} \times 100

Synergism analysis. Combination indices (CI) were calculated using the median-effect analysis taking advantage of the Compusyn software (ComboSyn Inc. NY, USA)\(^{27,28}\). The median-effect analysis considers both the shape and potency of the dose response curves on viability. The dose response curves of individual and combination treatments were linearized into a median effect plot of log(1/1 - f) vs log[D], where f is the fraction of dead cells, and D represents the drug concentration. CI values >1, =1, <1 are indicative of antagonism, additive effects, and synergism, respectively.

Confocal microscopy. EMT6/AR-1 cells were seeded at a density of 20,000 cells per well in a 8-well Nunc Lab-Tek II chambered cover glass (Thermo Fisher Scientific, MA, USA) and allowed to adhere for 24 hrs at 37 °C in a 5% CO2 and 95% air humidified incubator. The concentration of doxorubicin or pDox was kept at 5 μM for doxorubicin control, DNPs, and VDNPs. After incubation times of 2, 5, and 24 hours, cells were washed 3x with PBS, and Hoescht 33342 nuclei acid dye (Molecular Probes, Inc., Eugene, OR, USA) in PBS was added. Live cell imaging was performed using an Olympus FV1000 confocal microscope equipped with an oil immersion 60x lens. Excitation and emission wavelengths are as follows: for Hoescht 33342, excitation at 405 nm, and emission at 665 nm, and for doxorubicin, excitation at 488 nm, and emission at 580 nm.

Doxorubicin and pDox uptake and retention studies. 20,000 cells were seeded into 48-well plates and allowed to adhere for 24 h at 37 °C in a 5% CO2 and 95% air humidified incubator. The concentration of doxorubicin or pDox was kept at 5 μM for doxorubicin control, DNPs, and VDNPs. DNPs were either incubated alone, or with VDNPs dose-matched at the concentration of VES-H8R8, in VDNPs. To test Pgp inhibition, DNPs were also incubated with 20 μM of vitamin E succinate. Untreated cells were used as negative control to determine background. After 24 hours of treatment, cells were washed thrice with PBS, and harvested with trypsin. Cell fluorescence was analyzed using a BD Accuri C6 flow. Cell debris and doublets were gated out using FSH-H-I and at least 10,000 events were collected. The mean fluorescence intensity was measured on three biological repeats to evaluate the doxorubicin or pDox uptake and retention.

Mitochondrial membrane polarization assay. Mitochondrial membrane potential was assayed using the JC-1 probe (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylthiellazimi dazolycarbocyanine iodide) (Biotium Inc., CA, CA, 2020).
ΔΨm) were expressed using the following equation:

\[
\text{Relative Mitochondrial Membrane Potential} = \frac{JC_{\text{aggregate}} - JC_{\text{monomer\ treatment}}}{JC_{\text{aggregate}} - JC_{\text{monomer\ control}}} \times 100\%
\]

**ROS production assay.** Reactive oxygen species (ROS) in cells was detected using the cellular reactive oxygen species detection assay kit (ROS Deep Red) (abcam, ON, Canada) as per manufacturers protocols. 20,000 cells were seeded into 48-well plates and allowed to adhere for 24h at 37°C in 5% CO2 and 95% air humidified incubator. The cells were treated the next day for 2, 5, or 24 hours at the IC50 of VDNPs, where DNPs, VNPs, and DNPs+VNPs were dose-matched to the respective concentration of pDox or VES-H8R8 in VDNPs. Untreated control cells were used to measure background fluorescence in the FL-4 channel. Hydrogen peroxide (H2O2) at 1 mM was used as a positive control. Following treatment, the cells were washed with PBS thrice, and then the cells were incubated at 37°C in full media containing ROS deep red for 30 min. The cells were washed 3x with PBS, harvested, and placed on ice before measuring fluorescence in a flow cytometer within an hour. Cell debris and doublets were gated out using FSH-A vs FSH-H, and at least 10,000 events were collected. The mean fluorescence intensity was collected in the FL-4 channel (575 nm/25 nm) and averaged from three biological repeats. The results were expressed as fold increase in mean fluorescence intensity of treated cells relative to the untreated control group.

**Apoptosis and necrosis assay.** Apoptosis was measured using Annexin V-Cy5 (Biovision Inc, CA, USA) and Live or Dead Fixable Dead Cell Staining Kit (Deep Red Fluorescence) (Catalog # 22604, AAT Bioquest, CA USA). Apoptotic cells have exposed phosphatidylserine on the external cell membrane that binds to Annexin V-Cy5, while necrotic cells exhibit membrane damage that allows Live or Dead Fixable Dead Cell Staining dye to bind to DNA. Briefly, 20,000 EMT6/AR-1 cells were seeded into 48-well plates and allowed to adhere for 24h at 37°C in a 5% CO2 and 95% air humidified incubator. To analyze apoptosis, the EMT6/AR-1 cells were treated the next day for 2, 5, or 24 hours at the IC50 of VDNPs, where DNPs, VNPs, and DNPs+VNPs were dose-matched to the respective concentration of pDox or VES-H8R8 in VDNPs. Untreated control cells were used to measure background fluorescence in the FL-4 channel. Identical setup for the apoptosis assay was used to analyze necrotic cells, but only for a 24 hour incubation. Following treatment, floating cells were collected, adhered cells were harvested, washed with PBS, and then incubated with Annexin V-Cy5 (1 uL/1 mL) or with Live or Dead Fixable Dead Cell Staining Kit for 20 minutes at 25°C as per manufacturer’s protocol. Cells were then placed on ice before measuring fluorescence in a flow cytometer within an hour. Cell debris and doublets were gated out using FSH-A vs FSH-H, and at least 10,000 events were collected. Gates were set in the FL-4 channel (ex = 640 nm, em = 675 nm / 25 nm) for Annexin-V-Cy5 or Live or Dead Fixable Dead Cell Staining relative to unstained controls. Proportion of apoptotic or necrotic cells were averaged from 3 biological repeats.

**Statistical analysis.** All statistical analyses were performed using Graph Pad Prism version 6.00 for Windows (Graph Pad Software, San Diego, California, [www.graphpad.com](http://www.graphpad.com)). Differences among groups were assessed by one-way ANOVA with Bonferroni post hoc correction. Graphs are annotated where p-values are represented as *p ≤ 0.05, **p ≤ 0.01, or ***p ≤ 0.001. All data are presented as mean ± standard deviation.

**Results and Discussion**

**NP characterization and pDox release.** Blank NPs, singly loaded NPs, VES-H8R8-NPs (VNPs) and pDox-NPs (DNPs), and doubly loaded NPs, VES-H8R8-pDox-NPs (VDNPs) were prepared by nanoprecipitation in water. The average hydrodynamic sizes of the NPs were ~60 nm, indicating that the size of the NPs is independent of drug encapsulation. (Table 1) Most of the NPs also exhibited polydispersity indices below 0.20, indicative of narrow size distribution. The zeta potential of blank NPs was −12.9 ± 1.6 mV, while the zeta potential of singly loaded NPs were −4.6 ± 0.7 mV and 11.8 ± 1.8 mV for DNPs and VNPs, respectively. VDNPs, exhibited a zeta potential of 13.6 ± 1.7 mV. While all the values are in the range of neutral zeta potential (~20 to +20 mV), the trends from negative to positive charge is indicative of successful encapsulation of cationic VES-H8R8 and pDox. The more neutral zeta potential of DNPs is attributed to the protonated amine of pDox neutralizing the free acids of P(LA-co-TMCC)-g-PEG, while the more positive zeta potential of VDNPs is attributed to positive charges found within both pDox and VES-H8R8. The critical micelle concentration (CMC) of blank NPs and VNPs were 0.66 ± 0.12 µM and 1.25 ± 0.35 µM, respectively, in agreement with the CMC previously reported. DNPs achieved a pDox loading of 13.4 ± 1.6%, while VNPs achieved a VES-H8R8 loading
Interestingly, while pDox alone precipitates, encapsulated pDox is soluble (Fig. S2A), indicating successful drug encapsulation. VDNPs achieved similar drug loadings to each singly-loaded NPs, with pDox loading of 10.9 ± 1.3% and VES-H8R8 loading of 11.7 ± 0.7%, while the total drug loading amounts to 22.6%. The concentration of each drug in the encapsulated NPs is shown in Fig. S2B.

The NP stability was monitored by hydrodynamic size and polydispersity indices (PDI) measurements over time (Fig. 2A,B). Interestingly, while NPs with high drug loadings typically exhibit limited stability under physiological conditions, all formulations maintained size and PDI over at least 96 h at 37 °C. These results show that these P(LA-co-TMCC)-g-PEG NPs are stable in vitro and should be efficacious in vivo as they have been previously shown to be stable in serum, with a half-life of 71 ± 12 h and to enhance tumour accumulation of chemotherapeutics vs. that with conventional excipient delivery.

The pH-dependent release of doxorubicin (Dox) from the pDox prodru from the pDox prodru was validated by mass spectrometry, where all of the pDox was hydrolyzed within 24 h at pH 5.0 (Fig. S3). Dox release was studied at both physiological and acidic pH, using a dialysis test as previously reported. Free Dox control showed the expected rapid release, with >85% Dox released within 4 h at both pH 5.0 and 7.4 (Fig. 2C). Both DNPs and VDNPs showed limited Dox release (<20%) over 48 h at pH 7.4. However, the same formulations released up to 81% of Dox under acidic conditions (pH 5.0). Together, these results confirm the pH-sensitive release of pDox from the NPs. The similar results obtained for DNPs and VDNPs also indicate that VES-H8R8 co-encapsulation do not influence Dox hydrolysis and subsequent Dox release. More importantly, the release study at pH 5.0 is representative of late lysosomal acidic conditions, suggesting suitable endolysosomal escape of Dox following cell uptake.

Table 1. Physicochemical characteristics of blank NPs, and singly and doubly loaded NPs. aDynamic Light Scattering (DLS). bPolydispersity index (PDI) determined by DLS. cZeta potential measurement calculated with NPs in water at 1 mg/mL. dPyrene Method. eDoxorubicin Fluorescence in 10:1 DMSO-PBS against a standard curve. fAmino Acid Analysis.

| Name   | Size (d.nm) a | PDI b | Zeta Potential (mV) c | Critical Micelle Concentration (µM) d | pDox Loading (%) e | VES-H8R8 Loading (%) f |
|--------|---------------|-------|----------------------|--------------------------------------|------------------|----------------------|
| NP     | 64 ± 9        | 0.19 ± 0.04 | −12.9 ± 1.6 | 0.66 ± 0.12 |                      |                      |
| DNP    | 59 ± 3        | 0.20 ± 0.02 | −4.6 ± 0.7 | 13.4 ± 1.6 |                      |                      |
| VPN    | 57 ± 3        | 0.21 ± 0.02 | 11.8 ± 1.8 | 1.25 ± 0.35 | 11.7 ± 0.9 |                      |
| VDNP   | 68 ± 6        | 0.19 ± 0.01 | 13.6 ± 1.7 | 10.9 ± 1.3 | 11.7 ± 0.7 |                      |

Figure 2. Nanoparticle (NP) stability studies and pH-responsive release of palmityl-doxorubicin (pDox). Singly loaded NPs, pDox-NPs (DNPs) and vitamin E succinate modified octahistidine-octaarginine-NPs (VNPs), and doubly loaded NPs, vitamin E succinate modified octahistidine-octaarginine -pDox-NPS (VDNPs), were incubated in PBS at 37 °C and NP size (A) and polydispersity index (B) were measured every 24 hours. (C) pH-responsive release of pDOX loaded in singly loaded NPs, DNP, or doubly loaded NPs, VDNPs, at pH 7.4 vs 5.0. Free doxorubicin (Dox) was used as a dialysis control. Performed through a dialysis test at 37 °C for the indicated times. Unmodified doxorubicin was used as control.

of 15.1 ± 0.9%. Interestingly, while pDox alone precipitates, encapsulated pDox is soluble (Fig. S2A), indicating successful drug encapsulation. VDNPs achieved similar drugs loadings to each singly-loaded NPs, with pDox loading of 10.9 ± 1.3% and VES-H8R8 loading of 11.7 ± 0.7%, while the total drug loading amounts to 22.6%. The concentration of each drug in the encapsulated NPs is shown in Fig. S2B. The NP stability was monitored by hydrodynamic size and polydispersity indices (PDI) measurements over time (Fig. 2A,B). Interestingly, while NPs with high drug loadings typically exhibit limited stability under physiological conditions, all formulations maintained size and PDI over at least 96 h at 37 °C. These results show that these P(LA-co-TMCC)-g-PEG NPs are stable in vitro and should be efficacious in vivo as they have been previously shown to be stable in serum, with a half-life of 71 ± 12 h, and to enhance tumour accumulation of chemotherapeutics vs. that with conventional excipient delivery. The pH-dependent release of doxorubicin (Dox) from the pDox prodru was validated by mass spectrometry, where all of the pDox was hydrolyzed within 24 h at pH 5.0 (Fig. S3). Dox release was studied at both physiological and acidic pH, using a dialysis test as previously reported. Free Dox control showed the expected rapid release, with >85% Dox released within 4 h at both pH 5.0 and 7.4 (Fig. 2C). Both DNPs and VDNPs showed limited Dox release (<20%) over 48 h at pH 7.4. However, the same formulations released up to 81% of Dox under acidic conditions (pH 5.0). Together, these results confirm the pH-sensitive release of pDox from the NPs. The similar results obtained for DNPs and VDNPs also indicate that VES-H8R8 co-encapsulation do not influence Dox hydrolysis and subsequent Dox release. More importantly, the release study at pH 5.0 is representative of late lysosomal acidic conditions, suggesting suitable endolysosomal escape of Dox following cell uptake.
VPNs synergistically increase anti-cancer activity in a mdr breast cancer model. The anti-cancer activity of pDox and VES-H₈R₈ were assessed in the parental breast cancer cell line, EMT6/P, and the MDR breast cancer cell line, EMT6/AR-1, using the Presto Blue metabolic assay. The ability of treated cancer cells to metabolize Presto Blue was a proxy for anti-cancer activity (Tables 2, S1). pDox alone could not be tested at concentrations greater than 20 μM because of limited solubility. Importantly, the pH-responsive release of doxorubicin from pDox was demonstrated at pH 5.0 (Fig. S3). This supports the pH-responsive release of doxorubicin when pDox encapsulated NPs get trafficked through the endo-lysosomal pathway. While the half maximal inhibitory concentration (IC₅₀) of Dox in EMT6/P is 0.16 ± 0.02 μM, it increases up to 82.19 ± 7.36 μM in EMT6/AR-1, indicative of Dox efflux and MDR status in agreement with the literature²⁷,³⁸. The IC₅₀ of VES-H₈R₈ in EMT6/AR-1 and EMT6/P was 12.02 ± 1.94 μM and 11.12 ± 2.56 μM, respectively. The IC₅₀ of VES-H₈R₈ on the parental and that on MDR breast cancer cell lines were not significantly different, suggesting that the cell uptake and the mechanism of cancer cell death of VES-H₈R₈ are independent of the Pgp efflux. We also investigated the anti-cancer activity of the combination of free Dox and VES-H₈R₈ in both breast cancer cell lines. The molar ratio of Dox to VES-H₈R₈ was based on the drug loading of pDox and VES-H₈R₈ in NPs (Table 1). The combination of free Dox and VES-H₈R₈ in EMT6/P resulted in an IC₅₀ with a total drug concentration of 0.30 ± 0.03 μM, similar to that of Dox alone (0.16 ± 0.02 μM), indicating that VES-H₈R₈ did not increase the anti-cancer activity of Dox in the drug-sensitive cancer cell line. On the contrary, the combination of free Dox and VES-H₈R₈ in the MDR EMT6/AR-1 cells resulted in an IC₅₀ of 32.64 ± 1.70 μM requiring concentrations of 3.9-fold less Dox than Dox alone and 1.54-fold less VES-H₈R₈ than VES-H₈R₈ alone.

Next, we investigated the benefits of co-encapsulating VES-H₈R₈ and pDox in NPs. VPNPs exhibited an IC₅₀ in the low μM range in both EMT6/AR-1 and EMT6/P cells, similar to the anti-cancer activity of free VES-H₈R₈ (Table 2 and Fig. S1). Here, the total drug concentration is the sum of the concentrations of pDox and VES-H₈R₈, as the polymers used in the NPs were previously shown to be non-toxic to cancer cells³⁹. On the Dox-sensitive EMT6/P cells, DNs, the mixture of DNs and VPNPs, and VDNPs exhibited IC₅₀ in the range of 0.7–1.0 μM, attributed primarily to the anti-cancer activity of Dox. Here, co-encapsulating VES-H₈R₈ and pDox had no significant benefit against the parental cell line as the IC₅₀ of VPNPs was similar to DNs and the mixture of DNs and VPNPs. On the contrary, co-encapsulating VES-H₈R₈ and pDox improved treatment against the EMT6/AR-1 cells. The IC₅₀ of DNs and VPNPs in EMT6/AR-1 was 39.4 ± 2.87 μM and 14.00 ± 0.75 μM, respectively. The IC₅₀ of VDNPs in EMT6/AR-1 cells resulted in an IC₅₀ of 32.64 ± 1.70 μM requiring concentrations of 3.9-fold less Dox than Dox alone and 1.54-fold less VES-H₈R₈ than VES-H₈R₈ alone.

Table 2. IC₅₀ and combination indices of free drugs and drug-loaded NPs on the multi-drug resistant breast cancer cell line, EMT6/AR-1. a[Dox] and [VES-H₈R₈] determined by fluorescence measurements and amino acid analysis, respectively. bObtained from Presto Blue analysis of drug treated cells. cCalculated using CompuSyn.

| Name | Dox: VES-H₈R₈ Molar Ratio | IC₅₀ (μM, Total drug) | Combination Index |
|------|--------------------------|-----------------------|------------------|
| Dox  | 0: 1                     | 82.19 ± 7.36          |                  |
| VES-H₈R₈ | 1: 0                 | 12.02 ± 1.94         |                  |
| DNs  | 1: 0.37                  | 28.81 ± 2.87         | 0.60 ± 0.17      |
| VPNPs | 1: 0.37                | 39.40 ± 1.04         |                  |
| DNs + VPNPs | 1: 0.37 | 26.30 ± 2.30 | 0.99 ± 0.07     |
| VDNPs | 1: 0.37                | 16.09 ± 0.71         | 0.61 ± 0.04      |

The requirement of co-encapsulation is fundamental for in vivo translation as co-encapsulated drug nanoformulations administered in vivo can lead to superior tumor reduction and maintenance of drug ratios at the tumor site relative to the co-administered free drugs¹⁹. To assess the synergistic advantage of co-encapsulating VES-H₈R₈ and pDox in NPs, a combination index (CI) was calculated based on the median effect analysis²⁷. A median effect plot was produced by converting the dose response curves in Fig. S2C,D into log [(fa)¹−1]⁻¹ vs log (D), where fa is the fraction of non-viable cells and D is the drug concentration (Fig. S3). R² > 0.90 indicates statistical validity of the analysis and conforms to mass action law³⁸. Furthermore, nonparallel lines in the median effect plots infer non-exclusivity in the mechanism of action of VES-H₈R₈ and pDox. The median effect plot was further analyzed to obtain a CI. CI > 1 reflects drug antagonism, CI = 1 reflects drug additive effect, and CI < 1 shows drug synergism. The CI of the mixture of DNs and VPNPs was 0.99 ± 0.07, indicating that the mixture of DNs and VPNPs was additive in anti-cancer activity. Importantly, the CI of VDNPs was 0.61 ± 0.04, suggesting synergism of the co-encapsulated drugs against the MDR EMT6/AR-1 cells. In previous studies, a similar CI was achieved with NP formulations combining cytarabine and daunorubicin at a molar ratio of 5:1, which demonstrated improved survival of patients⁴⁰,⁴¹. The synergism of VDNPs may be attributed to the pH-dependent release of Dox from NPs, which would poison the topoisomerase II enzyme, coupled with the toxicity of VES-H₈R₈ by targeting of the mitochondria with subsequent depolarization. Furthermore, the dose reduction index indicates the fold decrease of a drug required...
to achieve the IC$_{50}$ in the combined treatment. The dose reduction index of pDox in VDNPs was 3.35 ± 0.23, indicating that a ~3.4 fold lower dose of pDox relative to DNPs was required to achieve the IC$_{50}$. Similarly, the dose reduction index of VES-H$_8$R$_8$ indicates that a ~3.3 fold lower dose of VES-H$_8$R$_8$ relative to VNPs is required to achieve the IC$_{50}$ of VDNPs. The reduced doses of both drugs would be beneficial in vivo where cardiotoxicity limits the maximum tolerated dose of single agent regimes$^{43}$.

**VDNPs enhances uptake, and retention of pDox.** To elucidate the synergistic mechanism of VDNPs, we investigated the time-dependent uptake of free Dox, DNPs and VDNPs in MDR EMT6/AR-1 cells over 2, 5, and 24 h, using confocal microscopy (Fig. 3A). In EMT6/AR-1 cells, the free Dox control showed minimal Dox fluorescence at all time points, confirming active drug efflux in MDR cancer cells. Cells treated with DNP and VDNP exhibited both punctate organelles and fluorescence in the cytosol and nucleus at 24 h after treatment, indicating that the NPs were in the endo-lysosomal compartments and the doxorubicin was in the cytosol and the nucleus, which is consistent with previous reports$^{45}$. Both DNPs and VDNPs showed time-dependent Dox accumulation up to 24 h post treatment. More importantly, VDNPs qualitatively exhibited enhanced uptake relative to DNPs and free Dox at all time points. DNP- and VDNP-treated cells exhibit punctate organelles, indicative of the endosomal compartment, as well as diffuse cytoplasmic fluorescence, indicative of endosomal escape$^{46}$. For both DNPs and VDNPs, there were indications of Dox release from the NPs and colocalization with cell nuclei, the intracellular target of Dox$^{44}$.

We further quantified the difference in Dox fluorescence between free Dox, DNPs and VDNPs using flow cytometry (Fig. 3B). Here, we incubated treatment groups for up to 24 h to measure time-dependent uptake. To measure retention, we incubated treatment groups for 24 h, then replenished with fresh media and incubated the cells for an additional 24 h to measure the amount of Dox retained after 48 h. At all time points, VDNPs delivered significantly more Dox in the MDR EMT6/AR-1 cells relative to DNPs and free Dox controls (***>0.001). Specifically, after a 24 h incubation, DNP-treated cells exhibited a mean fluorescence intensity (MFI)
indicative of active Dox efflux. We further validated the significance of co-encapsulating VES-H8R8 and pDox in increase in M.F.I. when co-encapsulated. As expected, free Dox treated cells exhibited minimal fluorescence, tion47. Importantly, the amount of Dox retained in VDNP-treated cells after 48 h is significantly increased com-
pared to free Dox, DNPs, and the mixture of DNPs and VNPs. The slightly more positive surface charge of
inhibits Dox efflux and could be used as a MDR sensitizer. However, VES-H8R8 comprises
octahistidine-octaarginine (VES-H8R8). Representative flow cytometry images can be found in Fig. S6. Data are
presented as a mean (n = 3) ± SD and statistical analysis was performed using one-way ANOVA and Tukey’s
multiple comparison test (* < 0.05, *** < 0.001).

Doubly loaded NPs induce mitochondrial depolarization and ROS. To deepen the understand-
ing of the synergistic mechanism of VDNPs, we confirmed the effect of VES-H8R8 on mitochondrial mem-
brane potential when encapsulated in NPs. To monitor mitochondrial membrane potential, JC-1 was used as
a mitochondrial-specific polarization probe. To avoid Dox fluorescence interference with the JC-1 assay, we
used vitamin E succinate that is an established Pgp efflux inhibitor, and VES-H8R8 was previously demonstrated to
inhibit Pgp efflux in the MDR EMT6/AR-1 cells4,48. Therefore, we hypothesized that encapsulated VES-H8R8
inhibits the Pgp efflux of Dox, leading to increased Dox accumulation in the cytosol. To test our hypothesis, we
incubated DNPs with free vitamin E succinate and evaluated Dox retention. After 24 h of incubation, followed by
24 h in fresh medium, the treated EMT6/AR-1 cells exhibited a 2.0 fold increase in Dox retention relative to DNPs
incubated at its IC50, where the other NP formulations were dose-matched to the respective drug concentration for either palmityl-Doxorubicin (pDox) or Vitamin E succinate modified octahistidine-octaarginine (VES-H8R8). Representative flow cytometry images can be found in Fig. S6. Data are presented as a mean (n = 3) ± SD and statistical analysis was performed using one-way ANOVA and Tukey’s multiple comparison test (* < 0.05, *** < 0.001).

Figure 4. NPs containing vitamin E succinate modified octahistidine-octaarginine (VNPs) depolarizes the mitochondrial membrane, and vitamin E succinate modified octahistidine-octaarginine-palmityl-doxorubicin-NPs (VDNPs) induce ROS in a time-dependent manner in multi-drug resistant (MDR) breast cancer. (A) Relative mitochondria polarization of EMT6/AR-1 cancer cells treated with VNP at the IC50 of VNP (14 µM) or treated at the IC50 of VES-H8R8 in VDNPs (4 µM). Negative controls include no treatment (Cntl) and blank nanoparticles (NPs) (orange bars). The positive control, Carbonyl cyanide m-chlorophenyl hydrazone (CCCP), decreased the mitochondria polarization. (B) VDNPs treatment induces more ROS relative to singly-loaded NPs, palmityldoxorubicin-NPs (DNPs) and VNPs, or a mixture of singly loaded NPs, VNPs+DNPs, in a time-
dependent manner. VDNPs was incubated at its IC50, where the other NP formulations were dose-matched to the respective drug concentration for either palmityl-Doxorubicin (pDox) or Vitamin E succinate modified octahistidine-octaarginine (VES-H8R8). Representative flow cytometry images can be found in Fig. S6. Data are presented as a mean (n = 3) ± SD and statistical analysis was performed using one-way ANOVA and Tukey’s multiple comparison test (* < 0.05, *** < 0.001).
equivalent dose of VES-H8R8 at the IC50 of VDNPs, relative to the no treatment group, indicating that depolarization is involved in the synergistic anti-cancer activity of VDNPs (* < 0.05). These results are consistent with the mitochondrial depolarization induced by VES-H8R8.54. Dox has also been demonstrated to indirectly depolarize cancer cell mitochondria through Dox-induced oxidative stress49–51. It is possible that the co-delivery of VES-H8R8 and pDox in VDNPs requires lower doses of each drug to affect mitochondria. VES-H8R8 may directly act upon the mitochondria while Dox induces intracellular events, such as reactive oxygen species (ROS) production, that indirectly affect mitochondria. The combined effects of encapsulated VES-H8R8 and pDox in VDNPs on mitochondrial depolarization further aid in understanding the synergistic cytotoxicity observed.

As both Dox and VES-H8R8 have been demonstrated to induce ROS, we investigated the effect of VDNPs on ROS levels, at the IC50 of VDNPs. As controls, the singly-loaded NPs and the mixture of singly loaded NPs were dose-matched to the respective drug in VDNPs. VDNPs significantly induced ROS at all time points (Fig. 4B). Specifically, VDNPs increased ROS levels to 224.9 ± 29.6%, 356.0 ± 23.5%, and 450.4 ± 40.8% relative to the no treatment group, upon incubation at 2, 5, and 24 h, respectively. Both DNPs and VNPs controls did not significantly induce an increase in ROS levels compared to no treatment. VDNPs significantly induced ROS levels compared to the mixture of DNPs and VNPs at 6 and 24 h of incubation, further highlighting the requirement of co-encapsulating VES-H8R8 and pDox to maximize synergism. (** < 0.001) The increase in ROS upon VDNPs treatment is consistent with the oxidative stress typically observed with both Dox and VES-H8R8 treatment54. It is clear that mitochondrial membrane depolarization and induction of ROS is involved in the synergistic cytotoxicity of VDNPs.

Doubly loaded NPs induce mainly apoptosis. Mitochondrial membrane depolarization and induction of ROS typically result in apoptosis52. Furthermore, VES-H8R8 was previously shown to induce apoptosis in the MDR EMT6/AR-1 cells44. To avoid fluorescent bleed over from Dox, apoptotic and necrotic cells were stained separately with Annexin V-Cy5 and 7-AAD. VDNPs incubated at its IC50 significantly increased the proportion of apoptotic cells at 2, 5, and 24 h of incubation relative to singly-loaded NPs, DNPs and VNPs, and their mixture (** < 0.01) (Fig. 5A). Specifically, VDNPs increased apoptotic levels to 21.7 ± 3.3%, 26.0 ± 6.3%, and 29.6 ± 5.6% upon incubation at 2, 5, and 24 h, respectively. Importantly, co-treating cells simultaneously with DNPs and VNPs did not significantly induce apoptosis relative to no treatment control group and both singly loaded NPs, further supporting the required co-encapsulation to trigger apoptosis. Thus, for annexin V-Cy5 binding, VDNP treatment likely resulted in EMT6/AR-1 cells exposing phosphatidylserine on the cell surface membrane. The induction of apoptosis by VDNPs agrees with the induced apoptosis observed with the treatment of EMT6/AR-1 cells with VES-H8R8, as previously shown44. As necrotic cells with compromised membranes could also stain for annexin-V, as a false positive for apoptosis, we evaluated the induction of necrosis upon VDNPs treatment. VDNPs significantly induced the proportion of necrotic cells relative to no treatment control (** < 0.01) (Fig. 5B). However, the increase in necrotic cell number was not as large as the increase in the proportion of apoptotic cells, suggesting that VDNPs treatment causes minimal membrane damage, and therefore mainly induces
apoptosis. This is consistent with the initial induction of apoptosis by doxorubicin on Jurkat cells after a 24 h treatment, followed by the induction of necrosis after a 60 h treatment²⁵.

Conclusion

We demonstrated, for the first time, the synergistic effect of VES-H₁R₆ and pDox co-encapsulation against MDR EMT6/AR-1 cells. We showed that co-encapsulation is superior to treatment with VNP and DNP together. Our investigation suggests that the synergistic mechanism involves increased cell uptake, enhanced Dox retention, Pgp inhibition, mitochondrial membrane depolarization, induction of ROS, and mainly apoptosis. This study highlights the significance of co-encapsulating a novel mitochondria depolarizer and Pgp efflux inhibitor, VES-H₁R₆, with a pH-sensitive prodrug of Dox in NPs to synergistically kill MDR breast cancer cells in vitro.

Received: 8 May 2019; Accepted: 4 May 2020;
Published online: 26 May 2020

References

1. Bugde, P. et al. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. Expert opinion on therapeutic targets 21, 511–530 (2017).
2. Indran, I. R., Tufo, G., Pervez, S. & Brenner, C. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochimica et Biophysica Acta (BBA)-Biomembranes 1807, 735–745 (2011).
3. Hall, M. D. et al. Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to topirone. Journal of Biological Chemistry 289, 21473–21489 (2014).
4. Ledwitch, K. V., Gibbs, M. E., Barnes, R. W. & Roberts, A. G. Cooperativity between verapamil and ATP bound to the efflux transporter P-glycoprotein. Biochemical Pharmacology 118, 96–108 (2016).
5. Strumberg, D. et al. A phase I study to determine the effect of regorafenib (REG) on the pharmacokinetics (PK) of substrates of P-glycoprotein (P-gp; digoxin) and breast cancer resistant protein (BCRP; rosuvastatin) in patients with advanced solid tumors. 27 (2016).
6. N. Stryepek et al. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP2. 6 10853 (2013).
7. Mechtner, E. et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clinical Cancer Research 4, 389–398 (1998).
8. Dattier, J. et al. ATP-dependent activity and mitochondrial localization of drug efflux pumps in doxorubicin-resistant breast cancer cells. Biochimica Et Biophysica Acta-GENERAL SUBJECTS 1861, 1075–1084 (2017).
9. Prochazka, L. et al. alpha-Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels. Apoptosis 15, 782–794 (2010).
10. Forrest, M. D. Why cancer cells have a more hyperpolarised mitochondrial membrane potential and emergent prospects for therapy, bioRxiv, 025197 (2015).
11. Bagkos, G., Koufopoulos, K. & Piperi, C. J. Mh A new model for mitochondrial membrane potential production and storage 83, 175–181 (2014).
12. Henkenius, K. et al. Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia. Leukemia Research 62, 56–63 (2017).
13. Horton, K., Stewart, K., Fonseca, S., Guo, Q. & Kelley, S. Mitochondria-penetrating peptides. Chemistry & Biology 15, 375–382 (2008).
14. Czapier, P. P., Delplace, V. & Shoichet, M. S. Cationic block amphiphiles show anti-mitochondrial activity in multi-drug resistant breast cancer cells. Journal of Controlled Release 305, 210–219 (2019).
15. Sykes, E. A., Chen, J., Zheng, G. & Chan, W. C. W. Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency. ACS Nano 8, 5696–5706 (2014).
16. Wang, J. Q. et al. The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment. ACS Nano 9, 7195–7206 (2015).
17. Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology 33, 941–951 (2015).
18. Zhang, R. X., Xue, H. Y., Eoh, J. Y. & Wu, X. Y. Nanomedicine of synergistic drug combinations for cancer therapy–Strategies and perspectives. Journal of Controlled Release 240, 489–503 (2016).
19. Zhang, R. X. et al. Polymer–lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin–mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. Nanomedicine: Nanotechnology, Biology and Medicine 12, 1279–1290 (2016).
20. J.E. Lancet et al. Final results of a phase III randomized trial of CPX-351 versus 7+ 3 in older patients with newly diagnosed high risk (secondary) AML, in, American Society of Clinical Oncology (2016).
21. R. van der Meel, T. Lammers & Hennink, W. E. Cancer nanomedicines: oversold or underappreciated?, in, Taylor & Francis (2017).
22. Li, F. et al. Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles. Journal of Visualized Experiments: JoVE 1279–1290 (2016).
23. Li, F. et al. Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles. Journal of Visualized Experiments: JoVE (2016).
24. Chou, T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological reviews 58, 621–681 (2006).
25. Ashton, J. C. Drug Combination Studies and Their Synergy Quantification Using the Chou–Talalay Method. Cancer research 75, 2400–2400 (2015).
26. Logie, J., Owen, S. C., McLaughlin, C. K. & Shoichet, M. S. PEG-graft density controls polymeric nanoparticle micelle stability. Chemistry of Materials 26, 2847–2855 (2014).
27. Lu, G. W. & Gao, P. Emulsions and microemulsions for topical and transdermal drug delivery, In: Handbook of non-invasive drug delivery systems, Elsevier, pp. 59–94 (2010).
28. Clogston, J. D. & Patri, A. K. Zeta potential measurement, In: Characterization of nanoparticles intended for drug delivery, Springer, pp. 63–70 (2011).
32. Lu, J. & Shoichet, M. S. Self-assembled polymeric nanoparticles of organocatalytic copolymerized D,L-lactide and 2-methyl 2-carboxytrimethylene carbonate. Macromolecules 43, 4943–4953 (2010).
33. Cai, K. et al. Dimeric drug polymeric nanoparticles with exceptionally high drug loading and quantitative loading efficiency. Journal of the American Chemical Society 137, 3458–3461 (2015).
34. Logie, J., Ganesh, A. N., Amam, A. M., Al-awar, R. S. & Shoichet, M. S. Preclinical evaluation of taxane-binding peptide-modified polymeric micelles loaded with docetaxel in an orthotopic breast cancer mouse model. Biomaterials 123, 39–47 (2017).
35. Price, D. J. et al. Poly (amino acid)–polymer graft copolymer nanoparticles for the acid-mediated release of doxorubicin. Chemical Communications 53, 8687–8690 (2017).
36. Piao, S. & Amaravadi, R. K. Targeting the lysosome in cancer. Annals of the New York Academy of Sciences 1371, 45–54 (2016).
37. Fang, X. J. et al. Doxorubicin induces drug resistance and expression of the novel CD44st via NF-kB in human breast cancer MCF-7 cells. Oncology reports 31, 2735–2742 (2014).
38. Shihendler, A. J. et al. Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. Molecular pharmacology 11, 2659–2674 (2014).
39. Shi, M., Ho, K., Keating, A. & Shoichet, M. S. Doxorubicin-Conjugated Immuno-Nanoparticles for Intracellular Anticancer Drug Delivery. Advanced Functional Materials 19, 1689–1696 (2009).
40. Zeng, X., Morgenstern, R. & Nystrom, A. M. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization of breast cancer cells by circumventing GST-mediated drug resistance. Biomaterials 35, 1227–1239 (2014).
41. Zhou, H. et al. A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity, Acta biomaterialia (2018).
42. Tardi, P. et al. In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy. Leukemia research 33, 129–139 (2009).
43. Thorn, C. F. et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and genomics 21, 440 (2011).
44. Yang, F., Teves, S. S., Kemp, C. J. & Henikoff, S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1845, 84–89 (2014).
45. Quadir, M. A. et al. Ligand-decorated click polypeptide derived nanoparticles for targeted drug delivery applications. Nanomedicine: Nanotechnology, Biology and Medicine 13, 1797–1808 (2017).
46. Seynhaeve, A. L., Dicheva, B. M., Hoving, S., Koning, G. A. & ten Hagen, T. L. Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imaging. Journal of controlled release 172, 330–340 (2013).
47. Fröhlich, E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. International journal of nanomedicine 7, 5377 (2012).
48. Tang, J. L. et al. Vitamin E reverses multidrug resistance in vitro and in vivo. Cancer Letters 336, 149–157 (2013).
49. Synowiec, E. et al. Doxorubicin differentially induces apoptosis, expression of mitochondrial apoptosis-related genes, and mitochondrial potential in BCR-ABL1-expressing cells sensitive and resistant to imatinib. BioMed research international, 2015 (2015).
50. Kuznetsova, A. V., Margreiter, R., Amberger, A., Saks, V. & Grimm, M. Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1813, 1144–1152 (2011).
51. Berthiaume, J. & Wallace, K. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell biology and toxicology 23, 15–25 (2007).
52. Grandinetti, G., Ingle, N. & Reineke, T. Interaction of Poly(ethyleneamine)-DNA Polyplexes with Mitochondria: Implications for a Mechanism of Cytotoxicity. Molecular Pharmacaceutics 8, 1709–1719 (2011).
53. K. Sugimoto, K. Tanayose, M. Sasaki, K. Hayashi, K. Oshimi. Low-dose doxorubicin-induced necrosis in Jurkat cells and its acceleration and conversion to apoptosis by antioxidants, in, Br J Haematol, pp. 229–238 (2002).

Acknowledgements
Funding for this work was provided by the Natural Sciences and Engineering Research Council of Canada (Discovery Grant to MSS and CREATE in M3 to PC). MSS also acknowledges support from the Tier 1 Canada Research Chair in Tissue Engineering.

Author contributions
All authors contributed to the study design, data analysis and manuscript writing. P.C. also characterized the modified peptide, doxorubicin, and NPs, and performed the experiments. V.D. also contributed in the doxorubicin modification. All authors approved the final version of the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-65450-x.

Correspondence and requests for materials should be addressed to M.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.